Please assess the completion status of the following clinical trial:

Trial Title: Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologic confirmation of non-small-cell lung cancer~* Stable systemic disease~* Maximum of one prior chemotherapy regimen for metastatic systemic disease~* Radiotherapy for local control or palliative bony lesions is allowed~* Karnofsky of greater than or equal to 70%~* Adequate hematologic, renal and liver function~Exclusion Criteria:~* Patients eligible for surgery of the brain~* Any previous chemotherapy for the brain metastasis~* Chemotherapy within 4 weeks or previous temozolomide~* Prior radiotherapy to the brain~* Radiation therapy to greater than 50% of the bone marrow~* Insufficient recovery from previous therapies~* Active nonmalignant systemic disease~* Inability to take oral medication~* Pregnant or nursing women~* Non use of adequate contraceptive techniques, negative urine pregnancy test is required~* Known AIDS related illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).